ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000447

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Identifieur interne : 000447 ( PascalFrancis/Corpus ); précédent : 000446; suivant : 000448

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Auteurs : Benedicte Ballanger ; Antonio P. Strafella ; Thilo Van Eimeren ; Mateusz Zurowski ; Pablo M. Rusjan ; Sylvain Houle ; Susan H. Fox

Source :

Archives of neurology : (Chicago) [ 0003-9942 ] ; 2010.

RBID : Pascal:10-0211459

Descripteurs français

Pascal (Inist)
- Hallucination visuelle, Maladie de Parkinson, Pathologie du système nerveux, Récepteur sérotoninergique.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Serotonine receptor, Visual hallucination.

Abstract

Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0003-9942`
A02	`01`			`@0 ARNEAS`
A03		`1`		`@0 Arch. neurol. : (Chic.)`
A05				`@2 67`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease`
A11	`01`	`1`		`@1 BALLANGER (Benedicte)`
A11	`02`	`1`		`@1 STRAFELLA (Antonio P.)`
A11	`03`	`1`		`@1 VAN EIMEREN (Thilo)`
A11	`04`	`1`		`@1 ZUROWSKI (Mateusz)`
A11	`05`	`1`		`@1 RUSJAN (Pablo M.)`
A11	`06`	`1`		`@1 HOULE (Sylvain)`
A11	`07`	`1`		`@1 FOX (Susan H.)`
A14	`01`			`@1 Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience @2 Toronto Western @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience @2 Toronto Western @3 USA @Z 2 aut. @Z 7 aut.`
A14	`03`			`@1 Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience @2 Toronto Western @3 USA @Z 4 aut.`
A14	`04`			`@1 Research Institute , University Health Network, University of Toronto @2 Toronto, Ontario @3 CAN @Z 2 aut.`
A20				`@1 416-421`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2048B @5 354000181009750070`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 10-0211459`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Archives of neurology : (Chicago)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Hallucination visuelle @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Visual hallucination @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Alucinación visual @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Récepteur sérotoninergique @5 09`
C03	`04`	`X`	`ENG`	`@0 Serotonine receptor @5 09`
C03	`04`	`X`	`SPA`	`@0 Receptor serotoninérgico @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 144`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0211459 INIST
ET :	Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
AU :	BALLANGER (Benedicte); STRAFELLA (Antonio P.); VAN EIMEREN (Thilo); ZUROWSKI (Mateusz); RUSJAN (Pablo M.); HOULE (Sylvain); FOX (Susan H.)
AF :	Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (2 aut., 7 aut.); Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (4 aut.); Research Institute , University Health Network, University of Toronto/Toronto, Ontario/Canada (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 2010; Vol. 67; No. 4; Pp. 416-421; Bibl. 28 ref.
LA :	Anglais
EA :	Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.
CC :	002B17; 002B17G
FD :	Hallucination visuelle; Maladie de Parkinson; Pathologie du système nerveux; Récepteur sérotoninergique
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Visual hallucination; Parkinson disease; Nervous system diseases; Serotonine receptor
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Alucinación visual; Parkinson enfermedad; Sistema nervioso patología; Receptor serotoninérgico
LO :	INIST-2048B.354000181009750070
ID :	10-0211459

Links to Exploration step

Pascal:10-0211459

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease</title>
<author><name sortKey="Ballanger, Benedicte" sort="Ballanger, Benedicte" uniqKey="Ballanger B" first="Benedicte" last="Ballanger">Benedicte Ballanger</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P." last="Strafella">Antonio P. Strafella</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Research Institute , University Health Network, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Eimeren, Thilo" sort="Van Eimeren, Thilo" uniqKey="Van Eimeren T" first="Thilo" last="Van Eimeren">Thilo Van Eimeren</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rusjan, Pablo M" sort="Rusjan, Pablo M" uniqKey="Rusjan P" first="Pablo M." last="Rusjan">Pablo M. Rusjan</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0211459</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0211459 INIST</idno>
<idno type="RBID">Pascal:10-0211459</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000447</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease</title>
<author><name sortKey="Ballanger, Benedicte" sort="Ballanger, Benedicte" uniqKey="Ballanger B" first="Benedicte" last="Ballanger">Benedicte Ballanger</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P." last="Strafella">Antonio P. Strafella</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Research Institute , University Health Network, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Eimeren, Thilo" sort="Van Eimeren, Thilo" uniqKey="Van Eimeren T" first="Thilo" last="Van Eimeren">Thilo Van Eimeren</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rusjan, Pablo M" sort="Rusjan, Pablo M" uniqKey="Rusjan P" first="Pablo M." last="Rusjan">Pablo M. Rusjan</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name>
<affiliation><inist:fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Serotonine receptor</term>
<term>Visual hallucination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hallucination visuelle</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Récepteur sérotoninergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-9942</s0>
</fA01>
<fA02 i1="01"><s0>ARNEAS</s0>
</fA02>
<fA03 i2="1"><s0>Arch. neurol. : (Chic.)</s0>
</fA03>
<fA05><s2>67</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BALLANGER (Benedicte)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STRAFELLA (Antonio P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VAN EIMEREN (Thilo)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ZUROWSKI (Mateusz)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RUSJAN (Pablo M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HOULE (Sylvain)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FOX (Susan H.)</s1>
</fA11>
<fA14 i1="01"><s1>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience</s1>
<s2>Toronto Western</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Research Institute , University Health Network, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>416-421</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2048B</s2>
<s5>354000181009750070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0211459</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Archives of neurology : (Chicago)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hallucination visuelle</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Visual hallucination</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Alucinación visual</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur sérotoninergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Serotonine receptor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor serotoninérgico</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>144</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0211459 INIST</NO>
<ET>Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease</ET>
<AU>BALLANGER (Benedicte); STRAFELLA (Antonio P.); VAN EIMEREN (Thilo); ZUROWSKI (Mateusz); RUSJAN (Pablo M.); HOULE (Sylvain); FOX (Susan H.)</AU>
<AF>Vivian M. Rakoff PET Centre and Centre for Addiction and Mental Health, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Movement Disorders Centre, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (2 aut., 7 aut.); Department of Psychiatry, Toronto Western Hospital, and Division of Brain, Imaging and Behaviour-Systems Neuroscience/Toronto Western/Etats-Unis (4 aut.); Research Institute , University Health Network, University of Toronto/Toronto, Ontario/Canada (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 2010; Vol. 67; No. 4; Pp. 416-421; Bibl. 28 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. Design: Case-control study. Setting: Academic research. Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Hallucination visuelle; Maladie de Parkinson; Pathologie du système nerveux; Récepteur sérotoninergique</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Visual hallucination; Parkinson disease; Nervous system diseases; Serotonine receptor</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Alucinación visual; Parkinson enfermedad; Sistema nervioso patología; Receptor serotoninérgico</SD>
<LO>INIST-2048B.354000181009750070</LO>
<ID>10-0211459</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000447 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000447 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0211459
   |texte=   Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri